
Rafael Sirera
3.5K posts

Rafael Sirera
@ProfSirera
Professor of Cell Biology at Universitat Politècnica de València, with a particular passion for molecular medicine and a strong interest in natural philosophy.



If there is a single discipline that has moved from being “foundational” to being strategically indispensable in biotechnology, it is immunology. The current pharmaceutical landscape makes this point unequivocally clear: among the top-selling drugs worldwide, 50% are monoclonal antibodies, and all of them act by modulating the immune system. For biotech students, this is not a theoretical trend—it is a direct indication of where innovation, funding, and clinical impact are concentrated. Let us examine these five molecules and how they reshape disease pathophysiology: 1⃣ Daratumumab (anti-CD38) Used in multiple myeloma, daratumumab targets CD38 expressed on malignant plasma cells. Its binding induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. Pathophysiologically, it reduces tumour burden while also modulating the immunosuppressive bone marrow niche by depleting regulatory immune subsets. 2⃣ Risankizumab (anti-IL-23 p19 subunit) Indicated in psoriasis and inflammatory bowel disease, risankizumab blocks IL-23, a key cytokine sustaining Th17 cells. This interrupts the IL-23/IL-17 axis, leading to reduced keratinocyte hyperproliferation and inflammation. The drug effectively rebalances aberrant immune activation at barrier tissues. 3⃣ Ocrelizumab (anti-CD20) Used in multiple sclerosis, ocrelizumab depletes CD20⁺ B cells. These cells contribute to antigen presentation, cytokine production, and autoantibody generation. Their depletion attenuates neuroinflammation and slows demyelination, demonstrating that MS is not solely T-cell driven but critically B-cell mediated. 4⃣ Pembrolizumab (anti-PD-1) A cornerstone of cancer immunotherapy, pembrolizumab blocks PD-1, releasing inhibitory checkpoints on T cells. Tumours exploit PD-1 signalling to evade immune surveillance; by inhibiting this pathway, pembrolizumab restores cytotoxic T-cell activity and promotes tumour clearance. It represents a paradigm shift from targeting the tumour to targeting the immune response to the tumour. 5⃣ Dupilumab (anti-IL-4Rα) Indicated in atopic dermatitis, asthma, and allergic diseases, dupilumab blocks IL-4 and IL-13 signalling via the shared IL-4Rα subunit. This suppresses Th2-driven inflammation, reducing IgE production, eosinophilia, and barrier dysfunction—central mechanisms in allergic pathology. These therapies illustrate a unifying principle: disease is increasingly understood as dysregulated immunity, whether in cancer, autoimmunity, or chronic inflammation. For biotechnology students, mastering immunology is no longer optional—it is the intellectual framework underpinning the most successful and transformative therapeutics of our time. nature.com/articles/d4157…






If there is a single discipline that has moved from being “foundational” to being strategically indispensable in biotechnology, it is immunology. The current pharmaceutical landscape makes this point unequivocally clear: among the top-selling drugs worldwide, 50% are monoclonal antibodies, and all of them act by modulating the immune system. For biotech students, this is not a theoretical trend—it is a direct indication of where innovation, funding, and clinical impact are concentrated. Let us examine these five molecules and how they reshape disease pathophysiology: 1⃣ Daratumumab (anti-CD38) Used in multiple myeloma, daratumumab targets CD38 expressed on malignant plasma cells. Its binding induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. Pathophysiologically, it reduces tumour burden while also modulating the immunosuppressive bone marrow niche by depleting regulatory immune subsets. 2⃣ Risankizumab (anti-IL-23 p19 subunit) Indicated in psoriasis and inflammatory bowel disease, risankizumab blocks IL-23, a key cytokine sustaining Th17 cells. This interrupts the IL-23/IL-17 axis, leading to reduced keratinocyte hyperproliferation and inflammation. The drug effectively rebalances aberrant immune activation at barrier tissues. 3⃣ Ocrelizumab (anti-CD20) Used in multiple sclerosis, ocrelizumab depletes CD20⁺ B cells. These cells contribute to antigen presentation, cytokine production, and autoantibody generation. Their depletion attenuates neuroinflammation and slows demyelination, demonstrating that MS is not solely T-cell driven but critically B-cell mediated. 4⃣ Pembrolizumab (anti-PD-1) A cornerstone of cancer immunotherapy, pembrolizumab blocks PD-1, releasing inhibitory checkpoints on T cells. Tumours exploit PD-1 signalling to evade immune surveillance; by inhibiting this pathway, pembrolizumab restores cytotoxic T-cell activity and promotes tumour clearance. It represents a paradigm shift from targeting the tumour to targeting the immune response to the tumour. 5⃣ Dupilumab (anti-IL-4Rα) Indicated in atopic dermatitis, asthma, and allergic diseases, dupilumab blocks IL-4 and IL-13 signalling via the shared IL-4Rα subunit. This suppresses Th2-driven inflammation, reducing IgE production, eosinophilia, and barrier dysfunction—central mechanisms in allergic pathology. These therapies illustrate a unifying principle: disease is increasingly understood as dysregulated immunity, whether in cancer, autoimmunity, or chronic inflammation. For biotechnology students, mastering immunology is no longer optional—it is the intellectual framework underpinning the most successful and transformative therapeutics of our time. nature.com/articles/d4157…



Few conditions are as common, as painful, and as surrounded by misconceptions as kidney stones—yet most explanations focus on myths rather than biology. 🌟 To understand why they truly form, and to move beyond oversimplified dietary blame, we need to look closely at the physiology and chemistry of the kidney itself. ▶️ Kidney stones develop when the finely regulated balance between water, ions, and metabolic waste in urine is disturbed. Under healthy conditions, urine remains sufficiently dilute to keep compounds such as calcium, oxalate, phosphate, and uric acid in solution. ▶️ When urine becomes concentrated—most often due to chronic low fluid intake—these substances can reach supersaturation and begin to crystallise. This process is governed by physical chemistry, not by a single “bad” food. ▶️ Microscopic crystals form routinely in many individuals and are usually eliminated without consequence. ▶️ Stones arise when crystal clearance fails. Reduced urine flow, prolonged urinary stasis, or deficiencies in natural crystallisation inhibitors such as citrate allow crystals to adhere to renal epithelial surfaces and grow. ▶️ Calcium oxalate stones, the most prevalent type, reflect a complex interaction between intestinal absorption, hepatic metabolism, gut microbiota, and renal calcium handling, rather than excessive calcium intake alone. ▶️ Other stone types emerge from distinct mechanisms: ➡️ uric acid stones are driven by acidic urine and purine metabolism; ➡️ infection stones result from urease-producing bacteria; ➡️ and rarer stones reflect inherited metabolic defects. Genetics, climate, and lifestyle modulate all these pathways. 🌟 Kidney stones, therefore, are not a simplistic dietary accident, but the visible outcome of a multifactorial disruption in renal homeostasis.


Uric Acid and Kidney Stones: Why Urine Chemistry Matters Uric acid is often linked to joint disorders like gout. However, its impact extends beyond joints to the kidneys, where it plays an important role in stone formation. How Uric Acid Behaves in Urine Uric acid is excreted by the kidneys into urine and exists in two forms: • Uric acid (less soluble) • Urate (more soluble) The balance between these forms is primarily determined by urine pH. The Critical Role of Urine pH When urine is alkaline, uric acid remains in its soluble urate form. When urine becomes acidic (pH < ~5.5), uric acid converts into its insoluble form, making it prone to crystallization. 👉 This is the key step in uric acid stone formation. Mechanism of Stone Formation Stone formation follows a sequence: 1️⃣ Supersaturation: High concentration of uric acid in urine 2️⃣ Acidic environment: Reduced solubility 3️⃣ Crystal formation 4️⃣ Aggregation → stone formation A Key Clinical Insight Uric acid stones may develop even when: • serum uric acid is normal • or only mildly elevated 👉 Because urine pH and concentration are more important than blood levels alone Dual Role of Uric Acid in Stones Uric acid contributes in two important ways: • Direct: forms uric acid stones • Indirect: acts as a nidus for calcium oxalate stones Uric acid crystals can facilitate calcium oxalate deposition, explaining their role in mixed stone formation. Why Does Urine Become Acidic? Urine acidity is closely linked to metabolic health. Common contributors include: • insulin resistance • metabolic syndrome • obesity • high animal protein intake • dehydration Insulin resistance, in particular, reduces ammonium production in the kidneys, leading to persistently low urine pH. Why Hydration Matters Low urine volume increases uric acid concentration, promoting supersaturation and crystallization. Adequate hydration: • dilutes urine • reduces crystal formation • lowers stone risk A Small but Important Insight Adequate magnesium intake may help reduce overall stone risk by influencing urinary crystallization, particularly in mixed stones involving calcium oxalate. Prevention and Practical Approach Risk can be reduced by: • adequate hydration • limiting excessive fructose intake • maintaining metabolic health • balanced diet • moderating excessive animal protein • in selected cases, urine alkalinization (under medical guidance) Final Thought Uric acid is not just a laboratory value or a joint-related issue. It reflects a deeper interaction between metabolism, kidney function, and urine chemistry. 👉 In many cases, the key is not just how much uric acid is present, but the environment in which it exists.



Why do we wake up with puffy eyes, swollen hands, and a more irritated throat when we have a cold? In this post I’ll explain the physiology behind it, what happens in the body during sleep. During sleep the body undergoes several physiological changes affecting posture, fluid dynamics, and hormonal regulation. Hormones such as antidiuretic hormone (ADH, or vasopressin) increase during the night. These shifts influence how fluids are distributed and how the body responds to inflammation. 1⃣ Why are the eyes puffy when we wake up? *⃣ Fluid accumulation While we sleep—particularly if lying on our back—venous and lymphatic drainage from the face slows down. Gravity acts differently than when we are upright, and muscle activity is minimal. As a result, fluid can temporarily accumulate in the soft tissues around the eyes, which are especially prone to swelling because the skin there is thin and the underlying connective tissue is loose. *⃣ Slower circulation During sleep, heart rate and blood pressure decrease. This lower circulatory drive can slightly favour the redistribution of fluid within tissues, contributing to the transient puffiness many people notice on waking. 2⃣ Why can the fingers appear swollen? A similar mechanism explains swelling in the hands. *⃣ Fluid redistribution When we lie down, gravity no longer pulls fluid towards the legs as it does when we are standing. This can favour fluid accumulation in the upper extremities, including the fingers—especially if there has been a high intake of salt or fluids before sleep. *⃣ Reduced movement Muscle contractions normally help pump venous blood and lymphatic fluid back towards the heart. During sleep this “muscle pump” is largely inactive, which can slow drainage and promote mild swelling. 3⃣ Why does the throat hurt more in the morning (especially during a cold)? *⃣ Dryness Saliva production decreases during sleep. If nasal congestion forces mouth breathing, the throat becomes even drier, worsening irritation. *⃣ Accumulation of secretions While lying down, mucus from the nasal passages and sinuses can collect in the throat. This can increase local inflammation and discomfort. *⃣ Inflammatory activity Respiratory infections trigger inflammation of the airway mucosa. After several hours of reduced swallowing and mucus clearance during sleep, the inflammatory effects may feel more pronounced upon waking. 4⃣ The role of ADH ADH (vasopressin) regulates how much water the kidneys retain. Its secretion follows a circadian rhythm and typically increases at night, reducing urine production and allowing uninterrupted sleep. This has physiological consequences Greater water retention during the night can contribute slightly to tissue swelling in susceptible areas. Reduced urine output means less overnight fluid elimination, which may amplify the feeling of congestion or discomfort during illness. Additional factors that worsen these symptoms • Nasal congestion, which promotes mouth breathing and throat dryness • Sleeping position, particularly lying flat, which can favour facial fluid accumulation and mucus pooling • Dietary factors, such as salty meals or inadequate hydration before sleep 5⃣ Why does the swelling disappear after getting up? Once we stand up, gravity assists fluid redistribution throughout the body. Movement activates the venous and lymphatic pumps, improving drainage and circulation. Within a short time, accumulated fluid is reabsorbed or redistributed, and the swelling gradually subsides. In short, puffy eyes, swollen fingers, and a sore throat on waking are the consequence of normal nocturnal physiological changes—fluid redistribution, hormonal regulation such as increased ADH, body position, and inflammatory responses during infection. Small adjustments in posture, hydration, and nasal care can often reduce these symptoms.














